Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com
     uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | The Route to RecoveryGo to article: In this issueGo to article: MimotopesGo to article: ContentsGo to article: NewsGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: Identifying a viable Covid-19 vaccine candidate and steps needed for its successful implementationGo to article: Impact of Covid-19 on patients with hepatocellular carcinomaGo to article: NSFGo to article: Novavax to receive $1.6B from Operation Warp Speed for the development of Covid-Go to article: FDA winners and losers in Covid-19 therapiesGo to article: Pfeiffer VacuumGo to article: Trials delayed due to Covid-19 begin to resumeGo to article: ILC Dover Go to article: The pharma industry briefingGo to article: From rare diseases to Covid-19: charting the history of Genomics EnglandGo to article: Covid-19: how will pharma cope with a looming recession?Go to article: Pandemic logistics: guaranteeing equitable accessGo to article: Pandemic logistics: Resolving manufacturing and distribution challengesGo to article: KugelmeiersGo to article: Q&A: how to find the right clinical trial participants with Innovative TrialsGo to article: Recce Pharma: a new frontier in the fight against AMRGo to article: Autism pipeline: are better therapies in sight?Go to article: How a new crystallography technique may speed up drug developmentGo to article: Psychedelics: a game-changer in mental health? Go to article: Graph technology: the remedy for broken supply chains is connected dataGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue